Toxicological and public good considerations for the regulation of nanomaterial-containing medical products

ISSN： 1474-0338

Source： Expert Opinion on Drug Safety, Vol.7, Iss.2, 2008-03, pp. : 103-106

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Toxicological considerations for intravitreal drugs

By Penha Fernando M Rodrigues Eduardo B Furlani Bruno A Dib Eduardo Melo Gustavo B Farah Michel E

Expert Opinion on Drug Metabolism and Toxicology, Vol. 7, Iss. 8, 2011-08 ,pp. : 1021-1034

Informa Healthcare

Access to resources Recommend Favorite

Toxicological considerations of acetylcholinesterase reactivators

By Voicu Victor Rădulescu Flavian Ştefan Medvedovici Andrei

Expert Opinion on Drug Metabolism and Toxicology, Vol. 9, Iss. 1, 2013-01 ,pp. : 31-50

Informa Healthcare

Access to resources Recommend Favorite

EMA's public statement on the use of thujone-containing products

Reactions Weekly, Vol. 1, Iss. 1409, 2012-01 ,pp. : 2-2

Adis International

Access to resources Recommend Favorite

Toxicological considerations for antithyroid drugs in children

By Karras Spiros Tzotzas Themistoklis Krassas Gerasimos E

Expert Opinion on Drug Metabolism and Toxicology, Vol. 7, Iss. 4, 2011-04 ,pp. : 399-410

Informa Healthcare

Access to resources Recommend Favorite

Medical Uses and Toxicological Profile of Cannabis

By Mascolo N.

Pharmacy and Pharmacology Communications, Vol. 6, Iss. 6, 2000-06 ,pp. : 231-234

Pharmaceutical Press

Access to resources Recommend Favorite